8-K current report · filed Nov 3, 2026

Tarsus Pharmaceuticals, Inc. (TARS) 8-K Current Report: November 3, 2026

Item 2.02Item EX-99.1TARS overview

Short answer

Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026.

Tarsus Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026
  • Exhibit 99.1 contains the company’s operating results and accompanying financial details

Item EX-99.1 · Exhibit EX-99.1

  • Q3 product sales $194.6M, up approximately 64% year over year, confirming strong XDEMVY commercial momentum
  • XDEMVY surpassed one million bottles dispensed and $1B cumulative net sales since launch
  • Refills represented approximately 20% of Q3 prescriptions, supporting growing retreatment and recurring demand
  • Net loss $668.3M, driven by $632.2M acquired IPR&D expenses from iRenix and Alkeus acquisitions
  • Cash, cash equivalents and marketable securities $309.6M, while acquisitions added $85.7M of contingent consideration liabilities

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tarsus Pharmaceuticals, Inc. 8-K filings

Get the next TARS 8-K as it lands

Follow TARS for push alerts, or ask the research agent what this filing means.